Dengue - Pipeline Review, H2 2014

Published: Sep, 2014 | Pages: 176 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Dengue - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Dengue - Pipeline Review, H2 2014', provides an overview of the Dengue's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Dengue, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dengue and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Dengue
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Dengue and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Dengue products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Dengue pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Dengue
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Dengue pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Dengue Overview 9
Therapeutics Development 10
Pipeline Products for Dengue - Overview 10
Pipeline Products for Dengue - Comparative Analysis 11
Dengue - Therapeutics under Development by Companies 12
Dengue - Therapeutics under Investigation by Universities/Institutes 16
Dengue - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Unknown Stage Products 21
Dengue - Products under Development by Companies 22
Dengue - Products under Investigation by Universities/Institutes 25
Dengue - Companies Involved in Therapeutics Development 26
United Therapeutics Corporation 26
GlaxoSmithKline plc 27
Merck & Co., Inc. 28
Takeda Pharmaceutical Company Limited 29
FIT Biotech Oyj 30
Biological E. Limited 31
Biotron Limited 32
Sarepta Therapeutics, Inc. 33
Medivir AB 34
BioDiem Ltd 35
NanoViricides, Inc. 36
SIGA Technologies, Inc. (Inactive) 37
Panacea Biotec Limited 38
Bharat Biotech International Limited 39
TechnoVax, Inc. 40
MacroGenics, Inc. 41
PTC Therapeutics, Inc. 42
Kineta, Inc. 43
Immunovaccine, Inc. 44
VaxInnate Corporation 45
Janssen Pharmaceuticals, Inc. 46
Cocrystal Pharma, Inc. 47
PaxVax 48
RFS Pharma, LLC 49
AltraVax Inc. 50
Visterra, Inc. 51
Arbovax, Inc. 52
Sanofi Pasteur SA 53
Themis Bioscience GmbH 54
Agilvax, Inc. 55
Humabs BioMed SA 56
Codagenix, Inc. 57
Dengue - Therapeutics Assessment 58
Assessment by Monotherapy Products 58
Assessment by Target 59
Assessment by Mechanism of Action 62
Assessment by Route of Administration 65
Assessment by Molecule Type 67
Drug Profiles 69
dengue vaccine [types 1,2,3,4] (tetravalent) - Drug Profile 69
TAK-003 - Drug Profile 72
dengue vaccine 3 - Drug Profile 74
dengue vaccine {rDEN1delta30, rDEN2/4delta30(ME), rDEN3delta30/31 and rDEN4delta30 }(tetravalent) - Drug Profile 76
celgosivir hydrochloride - Drug Profile 77
dengue vaccine 4 - Drug Profile 78
V-180 - Drug Profile 79
DNA Vaccine for Dengue - Drug Profile 80
DENV-1 PIV - Drug Profile 82
UV-4B - Drug Profile 83
modipafant - Drug Profile 84
ST-148 - Drug Profile 85
DengueCide - Drug Profile 86
TVX-005 - Drug Profile 87
dengue vaccine (DEN-2) - Drug Profile 88
AVI-6006 - Drug Profile 89
dengue vaccine - Drug Profile 90
DV-2-G460P - Drug Profile 91
ST-610 - Drug Profile 93
rOAS - Drug Profile 94
dengue vaccine (tetravalent) - Drug Profile 95
Vaccine for Dengue - Drug Profile 96
dengue vaccine - Drug Profile 98
dengue vaccines - Drug Profile 99
Dengue Virus Vaccine - Drug Profile 100
Vaccine for Dengue - Drug Profile 101
Monoclonal Antibody for Dengue - Drug Profile 102
GREDEN/V1-4 - Drug Profile 103
dengue (viral like particle) vaccine - Drug Profile 104
dengue vaccine - Drug Profile 105
dengue vaccine (DENV-2) - Drug Profile 106
dengue vaccine (tetravalent) - Drug Profile 107
dengue vaccine (DEN-1 and DEN-2) - Drug Profile 108
dengue vaccine - Drug Profile 109
Small Molecules to Inhibit Furin for Dengue - Drug Profile 110
VIS-513 - Drug Profile 111
DV-2-DeltaGVII - Drug Profile 112
DV-2-DeltaLIG - Drug Profile 113
dengue virus vaccine (tetravalent) - Drug Profile 114
ST-324 - Drug Profile 115
Small Molecules to Inhibit NS4b for Dengue - Drug Profile 116
Synthetic Peptides for West Nile Virus and Dengue Virus Infections - Drug Profile 117
Monoclonal Antibody for Infectious Disease - Drug Profile 118
Small Molecules Inhibiting M Protein for Dengue - Drug Profile 119
dengue vaccine - Drug Profile 120
Small Molecule for Viral Infections - Drug Profile 121
Small Molecule to Inhibit NS3 Protease for Dengue - Drug Profile 122
Viral PMO-X - Drug Profile 123
LCTA-949 - Drug Profile 124
DiTU - Drug Profile 125
BG-323 - Drug Profile 126
Small Molecules to Activate AMPK for Dengue - Drug Profile 127
Small Molecules to Inhibit Serine Protease for Viral Infections - Drug Profile 128
Dengue Fever Vaccine - Drug Profile 129
Monoclonal Antibodies to Inhibit prM and E Proteins for Dengue - Drug Profile 130
PAV-866 - Drug Profile 131
RNAi Oligonucleotide for Dengue - Drug Profile 132
Small Molecule Inhibitors of NS3 Protease for Dengue and West Nile Virus Infections - Drug Profile 133
Small Molecules to Inhibit Protease for Dengue - Drug Profile 134
ETX-101 - Drug Profile 135
Small Molecules to Inhibit RNA Dependent RNA Polymerase for Dengue Virus Infections - Drug Profile 136
Dengue Vaccine - Drug Profile 137
Small Molecule for Dengue - Drug Profile 138
Small Molecules for Dengue - Drug Profile 139
Small Molecules to Inhibit NS3 Helicase for Dengue - Drug Profile 140
RS-930 - Drug Profile 141
RS-961 - Drug Profile 142
RS-1137 - Drug Profile 143
RS-1142 - Drug Profile 144
RS-1145 - Drug Profile 145
Dengue Fever Vaccine - Drug Profile 146
dengue [DENV-2] vaccine - Drug Profile 147
Small Molecules to Inhibit NS3 Protease for Dengue and West Nile Virus Infections - Drug Profile 148
Small Molecules for Dengue - Drug Profile 149
Dengue Vaccine (Tetravalent) - Drug Profile 150
dengue vaccine (tetravalent) - Drug Profile 151
Dengue - Recent Pipeline Updates 152
Dengue - Dormant Projects 157
Dengue - Discontinued Products 158
Dengue - Product Development Milestones 159
Featured News & Press Releases 159
Appendix 170
Methodology 170
Coverage 170
Secondary Research 170
Primary Research 170
Expert Panel Validation 170
Contact Us 171
Disclaimer 171

List of Tables
Number of Products under Development for Dengue, H2 2014 15
Number of Products under Development for Dengue - Comparative Analysis, H2 2014 16
Number of Products under Development by Companies, H2 2014 18
Number of Products under Development by Companies, H2 2014 (Contd..1) 19
Number of Products under Development by Companies, H2 2014 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H2 2014 22
Comparative Analysis by Late Stage Development, H2 2014 23
Comparative Analysis by Clinical Stage Development, H2 2014 24
Comparative Analysis by Early Stage Development, H2 2014 25
Comparative Analysis by Unknown Stage Development, H2 2014 26
Products under Development by Companies, H2 2014 27
Products under Development by Companies, H2 2014 (Contd..1) 28
Products under Development by Companies, H2 2014 (Contd..2) 29
Products under Investigation by Universities/Institutes, H2 2014 30
Dengue - Pipeline by United Therapeutics Corporation, H2 2014 31
Dengue - Pipeline by GlaxoSmithKline plc, H2 2014 32
Dengue - Pipeline by Merck & Co., Inc., H2 2014 33
Dengue - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 34
Dengue - Pipeline by FIT Biotech Oyj, H2 2014 35
Dengue - Pipeline by Biological E. Limited, H2 2014 36
Dengue - Pipeline by Biotron Limited, H2 2014 37
Dengue - Pipeline by Sarepta Therapeutics, Inc., H2 2014 38
Dengue - Pipeline by Medivir AB, H2 2014 39
Dengue - Pipeline by BioDiem Ltd, H2 2014 40
Dengue - Pipeline by NanoViricides, Inc., H2 2014 41
Dengue - Pipeline by SIGA Technologies, Inc. (Inactive), H2 2014 42
Dengue - Pipeline by Panacea Biotec Limited, H2 2014 43
Dengue - Pipeline by Bharat Biotech International Limited, H2 2014 44
Dengue - Pipeline by TechnoVax, Inc., H2 2014 45
Dengue - Pipeline by MacroGenics, Inc., H2 2014 46
Dengue - Pipeline by PTC Therapeutics, Inc., H2 2014 47
Dengue - Pipeline by Kineta, Inc., H2 2014 48
Dengue - Pipeline by Immunovaccine, Inc., H2 2014 49
Dengue - Pipeline by VaxInnate Corporation, H2 2014 50
Dengue - Pipeline by Janssen Pharmaceuticals, Inc., H2 2014 51
Dengue - Pipeline by Cocrystal Pharma, Inc., H2 2014 52
Dengue - Pipeline by PaxVax, H2 2014 53
Dengue - Pipeline by RFS Pharma, LLC, H2 2014 54
Dengue - Pipeline by AltraVax Inc., H2 2014 55
Dengue - Pipeline by Visterra, Inc., H2 2014 56
Dengue - Pipeline by Arbovax, Inc., H2 2014 57
Dengue - Pipeline by Sanofi Pasteur SA, H2 2014 58
Dengue - Pipeline by Themis Bioscience GmbH, H2 2014 59
Dengue - Pipeline by Agilvax, Inc., H2 2014 60
Dengue - Pipeline by Humabs BioMed SA, H2 2014 61
Dengue - Pipeline by Codagenix, Inc., H2 2014 62
Assessment by Monotherapy Products, H2 2014 63
Number of Products by Stage and Target, H2 2014 66
Number of Products by Stage and Mechanism of Action, H2 2014 69
Number of Products by Stage and Route of Administration, H2 2014 71
Number of Products by Stage and Molecule Type, H2 2014 73
Dengue Therapeutics - Recent Pipeline Updates, H2 2014 157
Dengue - Dormant Projects, H2 2014 162
Dengue - Discontinued Products, H2 2014 163